What changed for Atrial Fibrillation
A plain English summary of what recently moved in the public data Voxsanity tracks for Atrial Fibrillation. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 378 to 383 (+5)
- Trials on record 2,962 to 3,004 (+42)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Atrial Fibrillation yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 72 trials tracked for Atrial Fibrillation that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05443594 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05443594) looked at a procedure called pulsed field ablation (PFA) for people with a heart rhythm condition. The trial ran in two phases — Phase 1 included 355 participants and Phase 2 included 314 participants. Not everyone completed the full study period: 325 finished in Phase 1 and 290 in Phase 2. The trial was measuring two main things: how often certain unwanted medical events occurred after the procedure, and how many participants met a definition of "treatment success" at 360 days after the procedure. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05809596 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05809596) enrolled 500 participants in a single group called the "Primary Analysis Subset." The trial was looking at a medical device — specifically measuring two things: first, whether there were any gaps or leaks around the device at 45 days after it was implanted (checked using a heart imaging scan called a TEE, or transoesophageal echocardiogram); and second, tracking a combined count of serious events — including death from any cause, stroke, blood clots travelling through the body, and major bleeding — over six month...
-
NCT03795298 · results posted 18 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03795298) enrolled 1,600 people in total — 797 in a group taking oral anticoagulants (blood-thinning tablets, used as the comparison group) and 803 who received a small implantable device called the WATCHMAN FLX, which is placed inside the heart to block a small pouch where blood clots can form. The trial was measuring two main things: first, how many people in each group experienced a stroke, died from any cause, or had a blood clot travel to another part of the body; and second, how many people experienced significant bl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04229472 · results posted 19 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04229472) enrolled participants across three groups: a Normal Subject Control Group, an Atrial Fibrillation Group, and an AcQMap Atrial Fibrillation Group. No participants were recorded as starting or completing the study in the Normal Subject Control Group. In the Atrial Fibrillation Group, 20 people started and 19 completed the study. In the AcQMap Atrial Fibrillation Group, 11 people started and 10 completed. The trial was focused on measuring electrical signals in the upper chambers of the heart — specifically looking...
-
NCT04926857 · results posted 1 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04926857) enrolled 973 people who already had a small heart-monitoring device — called a LINQ implantable cardiac monitor (ICM) — placed under their skin to continuously track their heart rhythm. The trial was measuring whether data collected by these devices could be used to predict when a person with atrial fibrillation (AF — an irregular heartbeat condition) was more likely to have a healthcare visit, such as a hospital admission, emergency department visit, or clinic appointment, where AF was a reason for that visit. O...
-
NCT04755283 · results posted 30 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04755283) enrolled 1,287 people in total — 427 in the abelacimab 90 mg group, 430 in the abelacimab 150 mg group, and 430 in the rivaroxaban group. The trial was measuring and comparing rates of bleeding events across the three groups. Rivaroxaban is an existing blood-thinning medicine, and abelacimab (MAA868) is an investigational medicine being studied in two different doses. The main thing the trial tracked was how often participants experienced a significant bleeding episode — either a "major bleed" (a serious bleed me...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05476250 · results posted 13 May 2025
According to the results reported on ClinicalTrials.gov, this trial involved 120 participants who were enrolled to test a Masimo sensor device (called INVSENSOR00057) and its ability to detect atrial fibrillation — an irregular heartbeat condition. Of the 120 people who started the trial, 99 completed it, while 21 did not complete it (the reasons were not reported in the data provided). The trial's main measurement focused on something called "specificity" — this means how often the device correctly identified people who did *not* have atrial fibrillation, without incorrectly flagging them as...
-
NCT03973931 · results posted 2 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 9,501 participants across four groups. Three groups received different types of digital "nudges" — automated messages designed to encourage people to pick up their prescription medications — while a fourth group received usual care with no extra prompts. The nudge approaches tested were: a general nudge, an optimised (more personalised) nudge, and an optimised nudge combined with an AI chat bot. The main thing being measured was how consistently people collected their medications over time, using pharmacy refill recor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02618577 · results posted 6 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02618577) enrolled 1,306 people in the edoxaban group and 1,302 people in the aspirin-or-placebo group — a total of 2,608 participants. The trial was measuring how often people experienced a stroke, a blood clot travelling to another part of the body (called systemic embolism), or death from a cardiovascular (heart or blood vessel) cause. It also tracked a number of secondary outcomes, including major heart events, death from any cause, serious bleeding, and quality of life. The reported data shows the main (primary) outc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05089877 · results posted 13 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05089877) was a single-group study — meaning everyone received the same treatment with no comparison group — that enrolled 39 participants. The trial was looking at a procedure called cardiac ablation for abnormal heart rhythms (specifically atrial fibrillation, atrial flutter, or atrial tachycardia). Of the 39 people who started, 28 completed the study and 11 did not finish. The trial measured two main things: whether serious events such as death, stroke, heart attack, or major bleeding occurred within 30 days of the proc...
-
NCT05072964 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 180 people who had a heart rhythm condition called paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes) and who had already tried at least one medication without success. The trial was testing the FARAPULSE Pulsed Field Ablation System, a device used to treat the abnormal electrical signals in the heart. Of the 180 people who started, 175 completed the study and 5 did not. The trial measured two main things: how many participants remained free of treatment failure over 12 months, and how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01924065 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 112 people with an irregular heart rhythm (atrial fibrillation) who were about to undergo a procedure called cardioversion (where the heart is reset back to a normal rhythm). Participants were split into two equal groups of 56. One group had a specialised heart ultrasound — called a transesophageal echocardiography, where a small probe is passed down the throat to get a close-up view of the heart — before their procedure. The other group received a course of blood-thinning medication (oral anticoagulants) beforehand....
-
NCT02697448 · results posted 20 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 135 people in total — 67 in the Propofol group and 68 in the Sevoflurane group. Both of these are types of anaesthetic (medicines used to keep patients unconscious during a procedure). The trial was comparing the two anaesthetics across a number of measurements, including how long the procedure took, how quickly patients could be taken off the breathing tube afterwards, and several recovery-related experiences the day after surgery such as pain, nausea or vomiting, and alertness. It also tracked whether participants e...
-
NCT04096963 · results posted 12 August 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a device called the WATCHMAN FLX, which is implanted inside the heart to close off a small pouch called the left atrial appendage — an area where blood clots can form in people with a type of irregular heartbeat. The trial enrolled 50 participants in total, of whom 46 completed the study. The trial was measuring two main things: whether the device was closing that pouch properly, and whether certain serious events occurred shortly after the procedure. The reported data shows that, for the primary "effectiveness" mea...
-
NCT03906461 · results posted 2 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03906461) enrolled 143 people and looked at how a heart procedure called radiofrequency ablation performed when using two specific tools together — the TactiCath SE catheter and a software feature called the Lesion Size Index (LSI). The LSI is a combined score that brings together how hard the catheter presses against the heart wall, how long the energy is applied, and how much electrical current is used, to give a single number representing how a heat-based scar (lesion) forms during the procedure. All 143 participants co...
-
NCT02731326 · results posted 3 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02731326) enrolled 131 people in the iHEART group and 131 people in the Usual Care group — 262 participants in total. The trial was measuring things related to an irregular heart rhythm condition called atrial fibrillation (AF), including how often the irregular rhythm came back, how long it took for those people to receive treatment, how many people needed treatment for a recurrence, participants' quality of life, and how much participants knew about their condition. The reported data shows the following for the three pr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04025710 · results posted 11 January 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 167 people in total, all placed into a single group. The trial was looking at a small heart-monitoring device (called BIOMONITOR III or BIOMONITOR IIIm) that is inserted under the skin to continuously record heart activity. Of the 167 people who started, 116 completed the study, while 51 did not finish. The primary outcome the trial was measuring was the number of participants who did not experience a "serious adverse device effect" (that is, a harmful event considered to be related to the device or its insertion pro...
-
NCT03455673 · results posted 22 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 3,160 people who all had atrial fibrillation (an irregular heartbeat condition). The trial was measuring whether a scoring tool called the "ATE score" — which stands for Atrial Thrombus Exclusion — could identify patients who had a blood clot inside the heart (called an atrial thrombus), as detected by a specialised heart scan called a transoesophageal echocardiogram. A score of zero on the ATE tool meant the patient had none of the listed risk factors, such as high blood pressure, heart failure, previous stroke, or a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04198701 · results posted 13 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04198701) enrolled a total of 421 participants across four groups: a Pilot group (38 people), a Roll-In group (60 people), and two main study groups — one for people with a type of irregular heartbeat called paroxysmal AF (164 enrolled) and one for persistent AF (159 enrolled). The trial was looking at a heart procedure using a system called PulseSelect PFA (pulsed field ablation), which targets specific areas of the heart involved in abnormal electrical signals. The study measured both how many participants experienced ce...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04187196 · results posted 13 November 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 73 people in total — 35 in a group given propofol (a sedative medicine) and 38 in a group given methohexital (another sedative medicine). Two participants in the propofol group did not complete the trial; everyone in the methohexital group did. The trial was looking at how quickly people recovered full awareness after being sedated, as well as a number of other time-related and physical measurements taken during and after the sedation procedure. The reported data shows that the main thing being measured — the time fr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04356040 · results posted 31 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04356040) enrolled people with a type of irregular heartbeat called paroxysmal atrial fibrillation (AF — where the heart rhythm comes and goes on its own). A total of 305 people took part in the main study, and a further 50 joined a related sub-study testing a slightly different approach using higher energy settings. All participants underwent a heart procedure using a catheter device called the TactiFlex SE, which uses radiofrequency (heat) energy to treat areas of the heart causing the irregular rhythm. The trial tracked...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04435769 · results posted 8 February 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 109 people in total — 42 in the apixaban group and 67 in the warfarin group — and all participants completed the study. The trial was conducted in people with a type of irregular heartbeat called non-valvular atrial fibrillation (AF). It looked at two things: how participants scored on two established risk-scoring tools (one estimating stroke risk, called CHA₂DS₂-VASc, and one estimating bleeding risk, called HAS-BLED, both scored from 0 to 9 with higher numbers meaning higher risk), and how many outpatient clinic vis...
-
NCT03650556 · results posted 27 April 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03650556) enrolled 224 participants, all placed in a single group. The trial was measuring two main things: how many participants experienced a serious adverse event (an unexpected, significant medical event) linked to the device or procedure within 7 days of the ablation, and how many participants remained free from returning episodes of irregular heart rhythms — specifically atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia (AT) — over a follow-up period. A total of 187 participants completed the full...
-
NCT02785991 · results posted 15 March 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,742 people who had been diagnosed with atrial fibrillation (an irregular heartbeat condition). Almost all of them — 1,741 out of 1,742 — completed the study. The trial was measuring how well a procedure called cryoablation (where cold energy is used to treat the heart tissue causing the irregular rhythm) prevented atrial fibrillation from coming back over 12 months, as well as how completely the procedure isolated certain areas of the heart, and how many unwanted events linked to the procedure were recorded. The re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03040661 · results posted 11 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 70 people in total — 35 in each group. All 70 participants completed the study, with no dropouts reported. The trial was comparing two methods of stopping bleeding at the groin access site after a heart procedure called cardiac ablation: one method used a specific type of stitch (called a "figure of 8 suture") placed at the site, while the other used manual pressure applied by hand. The trial measured how long each method took to stop the bleeding, how long it took for patients to leave the procedure room after the ab...
-
NCT02879448 · results posted 11 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02879448) enrolled 934 people in the Amulet group and 944 people in the WATCHMAN group — a total of 1,878 participants. Both devices are small implants placed inside the heart to close off a small pouch (called the left atrial appendage) in people with an irregular heartbeat, with the aim of reducing the risk of blood clots travelling to the brain or other organs. The trial measured and compared the two devices across several outcomes, including procedure-related complications, deaths, major bleeding events, strokes, and h...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02690649 · results posted 28 October 2021
According to the results reported on ClinicalTrials.gov, this trial involved 160 people in total, split evenly into two groups of 80. One group received health messaging (described as non-procedural), while the other group received no health messaging. The trial was looking at whether receiving health messages made a difference to how reliably participants took their medication, how often they logged into an online health portal, how much they knew about atrial fibrillation (an irregular heartbeat condition), and how many experienced serious health events during the study. The reported data s...
-
NCT03347695 · results posted 18 October 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a new surgical procedure for people who had both a longstanding irregular heart rhythm (called atrial fibrillation, or AF) and a heart valve problem requiring mitral valve surgery. A total of 140 people took part — 20 in a smaller pilot (test-run) group and 120 in the main group. The trial measured three main things: how many patients no longer had AF after surgery, how long a key part of the operation (called cardiopulmonary bypass, where a machine temporarily takes over the heart and lungs) lasted, and how many pat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03114124 · results posted 1 September 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03114124) enrolled 30 people in total — 15 in each of two groups. One group was treated using a Bipolar Ablation Catheter and the other using a MIFI Ablation Catheter. Both are types of specialised medical devices used to deliver radiofrequency (heat) energy to a precise area of the heart. All 30 participants completed the study. The trial was measuring the time it took for each device to produce a specific heart response — either a "junctional rhythm" (a particular change in the heart's electrical activity) or "complete h...
-
NCT03118518 · results posted 11 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03118518) enrolled 210 people with atrial fibrillation (an irregular heartbeat condition) — 108 were randomly assigned to receive a procedure called cryoballoon catheter ablation (where extreme cold is used to treat areas of the heart causing the irregular rhythm), and 102 were assigned to take antiarrhythmic drug therapy (medicines that aim to control heart rhythm). The trial was measuring how many people in each group were considered to have a "treatment success" at 12 months — meaning they had no return of the irregular...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 72 reported results for Atrial Fibrillation
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, research into atrial fibrillation is receiving a substantial level of public investment from the United States government, and that investment has been growing year on year. This rising trend is an encouraging signal, suggesting that atrial fibrillation is an active and expanding area of scientific interest. For patients, sustained and growing public funding generall...
See the full Atrial Fibrillation page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.